Compare SMID & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | STXS |
|---|---|---|
| Founded | 1960 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 210.0M |
| IPO Year | 1995 | 2004 |
| Metric | SMID | STXS |
|---|---|---|
| Price | $36.65 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 7.9K | ★ 614.4K |
| Earning Date | 11-13-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | $30,075,000.00 |
| Revenue This Year | N/A | $24.21 |
| Revenue Next Year | N/A | $29.83 |
| P/E Ratio | $16.52 | ★ N/A |
| Revenue Growth | 16.37 | ★ 19.62 |
| 52 Week Low | $25.13 | $1.54 |
| 52 Week High | $44.63 | $3.59 |
| Indicator | SMID | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 63.06 |
| Support Level | $33.89 | $2.47 |
| Resistance Level | $36.98 | $2.86 |
| Average True Range (ATR) | 2.13 | 0.13 |
| MACD | 0.25 | 0.04 |
| Stochastic Oscillator | 79.27 | 76.42 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.